Review



mt-sdna test  (MultiTarget Pharmaceuticals)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    MultiTarget Pharmaceuticals mt-sdna test
    Mt Sdna Test, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mt-sdna+test/stool+dna++mt+sdna++testing/pmc11461157-58-51-59
    Average 90 stars, based on 1 article reviews
    mt-sdna test - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: MT-sDNA test not cost effective for colorectal cancer screening
    Article Snippet: A multitarget stool DNA (MT-sDNA) test is not cost effective compared with the faecal immunochemical test (FIT) or colonoscopy for colorectal neoplasia screening in the US, according to the findings of a study published in Gastroenterology.. A Markov model of colorectal cancer (CRC) screening was used to evaluate the cost effectiveness of MT-sDNA testing, compared with FIT screening or colonoscopy, in cohorts of 100 000 patients at average risk of CRC, from a third-party payer perspective in the US over a lifetime time horizon.. Costs of MT-sDNA testing were based on Medicare reimbursement rates in patients aged 65 years or over and commercial insurance rates in patients aged 50–64 years.

    Article Title: Multi-Target Stool DNA Testing for Colorectal Cancer Screening: Emerging Learning on Real-world Performance.
    Article Snippet: 53.• Berger BM, Kisiel JB, Imperiale TF, Geenen DJ, Heigh RI, Mahoney DW, et al. Low incidence of aerodigestive cancers in patients with negative results from colonoscopies, regardless of findings from multitarget stool DNA tests.

    Article Title: Stool-based testing for post-polypectomy colorectal cancer surveillance safely reduces colonoscopies: The MOCCAS study.
    Article Snippet: Test characteristics of the mt-sDNA test in the post-polypectomy group at the thresholds used in the biennial and the triennial strategies that are at least equivalent to colonoscopy surveillance. a N = 2226 Colonoscopy Multitarget Stool DNA Test Score ≥ 270 (Biennial testing) Score ≥ 185 (Triennial testing) Cases Positive cases Sensitivity (95% CI) Positive cases Sensitivity (95% CI) Advanced neoplasia 322 146 45% (40-51%) 189 59% (53-64%) Colorectal cancer 7 6 86% (42-99%) 6 86% (42-99%) Advanced adenomas 222 90 41% (34-47%) 114 51% (45-58%) Advanced serrated polyps 93 50 54% (43-64%) 69 74% (63-82%) Non-advanced neoplasia 993 193 19% (17-22%) 301 30% (27-33%) Non-advanced adenomas 789 149 19% (16-22%) 225 29% (25-32%) Non-advanced serrated polyps 204 44 22% (16-28%) 76 37% (31-44%) Controls Negative controls Specificity (95% CI) Negative controls Specificity (95% CI) No colorectal neoplasia b 911 795 87% (85-89%) 722 79% (76-82%) No lesions 716 628 88% (85-90%) 577 81% (77-83%) a Annual testing with the mt-sDNA test was considered not relevant, due to the high costs of the test and was therefore not evaluated. b Colorectal neoplasia = colorectal cancer, advanced adenoma, advanced serrated polyp, non-advanced adenoma, and non-advanced serrated polyp.

    Article Title: Characteristics of a cost-effective blood test for colorectal cancer screening
    Article Snippet: Sensitivity to detect advanced adenomas spans the false-positive rate under the CMS coverage decision (10%), and the maximum sensitivity to advanced adenomas explored (50%) goes beyond the advanced adenoma sensitivity of any existing noninvasive test: sensitivity to advanced adenomas for mt-sDNA was 42% for the first-generation test , 43.4% for the next-generation mt-sDNA test , and 46% for a multitarget stool RNA test ( ).



    Similar Products

    mt-sdna screening test  (Wolters Kluwer Health)
    90
    Wolters Kluwer Health mt-sdna screening test
    Mt Sdna Screening Test, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mt-sdna+test/mt+sdna+screening+test/pm40569294-115-19-2
    Average 90 stars, based on 1 article reviews
    mt-sdna screening test - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    multi-target stool dna (mt-sdna) test (marketed as cologuard)  (Exact Sciences Corporation)
    90
    Exact Sciences Corporation multi-target stool dna (mt-sdna) test (marketed as cologuard)
    Multi Target Stool Dna (Mt Sdna) Test (Marketed As Cologuard), supplied by Exact Sciences Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mt-sdna+test/multi+target+stool+dna+test+cologuard/pm39992481-15-13-27
    Average 90 stars, based on 1 article reviews
    multi-target stool dna (mt-sdna) test (marketed as cologuard) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    triennial mt-sdna test  (Guardant Health)
    90
    Guardant Health triennial mt-sdna test
    Sensitivity, Specificity, and Realistic Adherence Assumptions for Each Screening Strategy
    Triennial Mt Sdna Test, supplied by Guardant Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mt-sdna+test/triennial+mt+sdna+test/pmc11739995-70-12-21
    Average 90 stars, based on 1 article reviews
    triennial mt-sdna test - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    mt-sdna test  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals mt-sdna test
    Sensitivity, Specificity, and Realistic Adherence Assumptions for Each Screening Strategy
    Mt Sdna Test, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mt-sdna+test/stool+dna++mt+sdna++testing/pmc11461157-58-51-59
    Average 90 stars, based on 1 article reviews
    mt-sdna test - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    stool dna (mt-sdna) test  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals stool dna (mt-sdna) test
    Sensitivity, Specificity, and Realistic Adherence Assumptions for Each Screening Strategy
    Stool Dna (Mt Sdna) Test, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mt-sdna+test/stool+dna++mt+sdna++testing/pm39218164-91-9-8
    Average 90 stars, based on 1 article reviews
    stool dna (mt-sdna) test - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    next-generation mt-sdna test  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals next-generation mt-sdna test
    <t>ROC</t> curves and AUC for (A) CRC a (sensitivity category 1) and (B) any advanced neoplasia b (CRC or APLs, sensitivity categories 1–2) vs 1-specificity for the absence of advanced neoplasia (categories 3–6) for the first-generation and next-generation <t>mt-sDNA</t> tests in the DeeP-C test set. APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.
    Next Generation Mt Sdna Test, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mt-sdna+test/stool+dna++mt+sdna++testing/pmc11401593-148-55-13
    Average 90 stars, based on 1 article reviews
    next-generation mt-sdna test - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    mt-sdna tests  (Exact Sciences Corporation)
    90
    Exact Sciences Corporation mt-sdna tests
    <t>ROC</t> curves and AUC for (A) CRC a (sensitivity category 1) and (B) any advanced neoplasia b (CRC or APLs, sensitivity categories 1–2) vs 1-specificity for the absence of advanced neoplasia (categories 3–6) for the first-generation and next-generation <t>mt-sDNA</t> tests in the DeeP-C test set. APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.
    Mt Sdna Tests, supplied by Exact Sciences Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mt-sdna+test/mt+sdna+tests/pmc10964930-100-8-25
    Average 90 stars, based on 1 article reviews
    mt-sdna tests - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    multi-target stool dna (mt-sdna) screening test  (Exact Sciences Corporation)
    90
    Exact Sciences Corporation multi-target stool dna (mt-sdna) screening test
    <t>ROC</t> curves and AUC for (A) CRC a (sensitivity category 1) and (B) any advanced neoplasia b (CRC or APLs, sensitivity categories 1–2) vs 1-specificity for the absence of advanced neoplasia (categories 3–6) for the first-generation and next-generation <t>mt-sDNA</t> tests in the DeeP-C test set. APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.
    Multi Target Stool Dna (Mt Sdna) Screening Test, supplied by Exact Sciences Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mt-sdna+test/multi+target+stool+dna+test+cologuard/pmc10666720-104-13-26
    Average 90 stars, based on 1 article reviews
    multi-target stool dna (mt-sdna) screening test - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Sensitivity, Specificity, and Realistic Adherence Assumptions for Each Screening Strategy

    Journal: JAMA Network Open

    Article Title: Cost-Effectiveness of Noninvasive Colorectal Cancer Screening in Community Clinics

    doi: 10.1001/jamanetworkopen.2024.54938

    Figure Lengend Snippet: Sensitivity, Specificity, and Realistic Adherence Assumptions for Each Screening Strategy

    Article Snippet: We simulated 4 screening strategies: no screening, annual FIT, biennial FIT, , triennial mt-sDNA test, and a triennial blood test (Shield; Guardant Health).

    Techniques:

    Projected CRC Outcomes for Screening Programs Based on a FIT, mt-sDNA Test, or a Blood-Based Test <xref ref-type= a " width="100%" height="100%">

    Journal: JAMA Network Open

    Article Title: Cost-Effectiveness of Noninvasive Colorectal Cancer Screening in Community Clinics

    doi: 10.1001/jamanetworkopen.2024.54938

    Figure Lengend Snippet: Projected CRC Outcomes for Screening Programs Based on a FIT, mt-sDNA Test, or a Blood-Based Test a

    Article Snippet: We simulated 4 screening strategies: no screening, annual FIT, biennial FIT, , triennial mt-sDNA test, and a triennial blood test (Shield; Guardant Health).

    Techniques:

    Projected Cost-Effectiveness Outcomes <xref ref-type= a " width="100%" height="100%">

    Journal: JAMA Network Open

    Article Title: Cost-Effectiveness of Noninvasive Colorectal Cancer Screening in Community Clinics

    doi: 10.1001/jamanetworkopen.2024.54938

    Figure Lengend Snippet: Projected Cost-Effectiveness Outcomes a

    Article Snippet: We simulated 4 screening strategies: no screening, annual FIT, biennial FIT, , triennial mt-sDNA test, and a triennial blood test (Shield; Guardant Health).

    Techniques:

    ROC curves and AUC for (A) CRC a (sensitivity category 1) and (B) any advanced neoplasia b (CRC or APLs, sensitivity categories 1–2) vs 1-specificity for the absence of advanced neoplasia (categories 3–6) for the first-generation and next-generation mt-sDNA tests in the DeeP-C test set. APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.

    Journal: Gastro Hep Advances

    Article Title: Algorithm Development and Early Performance Evaluation of a Next-Generation Multitarget Stool DNA Screening Test for Colorectal Cancer

    doi: 10.1016/j.gastha.2024.05.002

    Figure Lengend Snippet: ROC curves and AUC for (A) CRC a (sensitivity category 1) and (B) any advanced neoplasia b (CRC or APLs, sensitivity categories 1–2) vs 1-specificity for the absence of advanced neoplasia (categories 3–6) for the first-generation and next-generation mt-sDNA tests in the DeeP-C test set. APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.

    Article Snippet: APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.

    Techniques:

    Performance of the Next-Generation mt-sDNA Test Compared With Historical Performance of the First-Generation mt-sDNA Test in the DeeP-C Test Set

    Journal: Gastro Hep Advances

    Article Title: Algorithm Development and Early Performance Evaluation of a Next-Generation Multitarget Stool DNA Screening Test for Colorectal Cancer

    doi: 10.1016/j.gastha.2024.05.002

    Figure Lengend Snippet: Performance of the Next-Generation mt-sDNA Test Compared With Historical Performance of the First-Generation mt-sDNA Test in the DeeP-C Test Set

    Article Snippet: APL, advanced precancerous lesion; AUC, area under the curve; CRC, colorectal cancer; mt-sDNA, multitarget stool DNA; ROC, receiver operating characteristic. a Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.03 (95% CI, 0.004–0.05); P = .02. b Difference in area under the ROC curve for the next-generation mt-sDNA test vs the first-generation mt-sDNA test: 0.04 (95% CI, 0.02–0.06); P < .0001.

    Techniques: